Indrayani Biotech reported a consolidated net profit of Rs 2.16 crore for FY26, turning around from a loss. However, the auditor issued a qualified opinion citing unconfirmed balances and subsidiary accounting issues.
Indrayani Biotech Reports Profit Turnaround Amidst Qualified Audit
Consolidated Net Profit: Rs 2.16 crore (FY26) vs. Loss: Rs 6.11 crore (FY25)
Standalone Net Profit: Rs 0.70 crore (FY26) vs. Rs 1.45 crore (FY25)
Reader Takeaway: Consolidated profit turnaround is positive, but auditor's qualified opinion raises concerns about financial transparency.